Resistance of Beta 2 Microglobulin Null Mice to Sepsis

Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力

基本信息

  • 批准号:
    7256520
  • 负责人:
  • 金额:
    $ 25.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-07-01 至 2009-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Beta2 microglobulin knockout mice are deficient in CD8+ T cells and natural killer T cells. Compared to wild type mice, beta2 microglobulin knockout mice exhibit improved survival during sepsis caused by cecal ligation and puncture (CLP). Further depletion of natural killer cells by injection of anti-asialoGM1 confers near complete resistance to CLP-induced mortality. The mechanisms underlying these observations are unknown. However, two potential mechanisms have high probability. Firstly, CD8+ T, natural killer T and natural killer cells can impact innate immune responses by amplifying production of pro-inflammatory cytokines and chemokines. These cell populations can also cause direct cellular injury during inflammation. Therefore, it is hypothesized that CD8+ T, natural killer T and natural killer cells facilitate or directly mediate sepsis-induced mortality by amplifying the pro-inflammatory response and/or causing direct cellular injury. Secondly, beta2 microgiobulin comprises the beta chain of the class I major histocompatibility complex and the non-classical antigen-presenting molecule CD1. Both of these molecules are important for presentation of self and foreign antigens, respectively, but their roles in regulating inflammatory responses during sepsis are unknown. It is further hypothesized that the class I major histocompatibility complex, CD1 and/or unrecognized beta2 microglobulin-associated molecules play a role in modulating the immune response during sepsis. This research project is designed to test these hypotheses. The following specific aims are proposed: Aim 1: To determine the specific contributions of CD8+ T, natural killer T and natural killer cells, the class I major histocompatibility complex and CD1 to the pathogenesis of lethal intra-abdominal sepsis. Mortality, bacterial counts, organ injury, cardiovascular function and acid-base balance will be measured following CLP in control mice and mice that are deficient in these cell populations and antigen-presenting molecules. Specific Aim 2: To determine the functional roles of CD8+ T, natural killer T and natural killer cells, the class I major histocompatibility complex and CD1 in regulating the pro-inflammatory response during lethal intra-abdominal sepsis. Intra-abdominal and systemic cytokine and chemokine production will be measured following CLP in control mice and mice that are deficient in CD8+ T, natural killer T and natural killer cells, the class I major histocompatibility complex and CD1. Specific Aim 3: To determine the role of cytolytic mechanisms in the pathogenesis of lethal intra-abdominal sepsis. We will evaluate expression of perforin, granzymes, Fas and FasL in control mice and mice that are deficient in CD8+ T, natural killer T and natural killer cells after CLP. The functional roles of the perforin/granzyme and Fas-FasL pathways will be determined by assessing survival, cardiovascular function, organ injury and acid-base balance in perforin-deficient and FasL-deficient mice. These studies are designed to define new mechanisms that are important in the pathogenesis of septic shock with the ultimate goal of developing new treatments for this lethal disease process.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD R SHERWOOD其他文献

EDWARD R SHERWOOD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD R SHERWOOD', 18)}}的其他基金

Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
  • 批准号:
    10550138
  • 财政年份:
    2020
  • 资助金额:
    $ 25.06万
  • 项目类别:
Macrophage mitochodrial reprogramming and innate immune memory
巨噬细胞线粒体重编程和先天免疫记忆
  • 批准号:
    10333362
  • 财政年份:
    2020
  • 资助金额:
    $ 25.06万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10296894
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10461115
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Equipment supplement to "Training Innate Immunity: A new approach to the treatment of sepsis"
《训练先天免疫:治疗脓毒症的新方法》的设备补充
  • 批准号:
    10794766
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Equipment Supplement request for a BD LSR Fortessa Flow Cytometer
BD LSR Fortessa 流式细胞仪的设备补充请求
  • 批准号:
    9275190
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Training Innate Immunity: A new approach to the treatment of Sepsis
训练先天免疫:治疗脓毒症的新方法
  • 批准号:
    10669060
  • 财政年份:
    2016
  • 资助金额:
    $ 25.06万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    7811704
  • 财政年份:
    2003
  • 资助金额:
    $ 25.06万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    8292209
  • 财政年份:
    2003
  • 资助金额:
    $ 25.06万
  • 项目类别:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
Beta 2 微球蛋白无效小鼠对脓毒症的抵抗力
  • 批准号:
    8578744
  • 财政年份:
    2003
  • 资助金额:
    $ 25.06万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 25.06万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了